Program

21st Annual SoCalBio Conference

September 19, 2019 — The Westin Long Beach, CA

The conference will be preceded by a CEO reception and dinner on September 18, from 5 to 9 pm

SoCalBio is a nonprofit, member-supported trade association that promotes life-science research, development, manufacturing, job creation and overall economic growth in the six counties of the Greater Los Angeles region (Los Angeles, Orange, Ventura, Santa Barbara, Riverside, and San Bernardino). The Council’s programs help local firms gain access to capital, potential partners and business support services. The annual SoCalBio Investor & Partnering Conference has grown to become the region’s premier showcase for emerging life-science companies and technologies.

This year, the SoCalBio Conference will feature:

  • About 30 emerging, pre-screened and mentored bioscience companies,
  • High-quality keynote presentations touching on market and technology trends,
  • Plenary sessions
  • Cocktail reception, good food and ample opportunities for networking

Conference Agenda

7:30 AMRegistration and Breakfast
8:15 AM — 8:30 AM

Opening Remarks

  • Robert Greenberg, MD, PhD, Executive Chairman, Alfred Mann Foundation, and Chairman, SoCalBio
  • Ahmed Enany, President & CEO, SoCalBio
8:30 AM — 8:40 AM

Acknowledgment of the SoCalBio Innovation Catalyst Program Members

  • Peter Blaisdell, PhD, Independent Consultant, Drug and Biologic Development, and Chair, SoCalBio Innovation Catalyst Program
8:40 AM—9:10 AM

The Bioscience Industry Funding Landscape

A leading investment professional provides a data-rich update on bioscience industry investment trends, particularly the funding prospects of emerging biotech, MedTech, and digital health companies.

      • Soraya M. Scroggins, Managing Director, Investment Banking and Global Healthcare, Barclays
9:10 AM—9:30 AM

The Greater Los Angeles Biotech Hub: Why Here? Why Now?

The Greater Los Angeles Metro Area (including Los Angeles County, Orange County, the Inland Empire and Ventura County) is home to a growing biotech cluster that includes more than 300 companies. One of these is Dantari Pharmaceuticals (Newbury Park, CA) which was recently founded and funded by Ventura County-based VC firm Westlake Village BioPartners. Dantari’s chief, Dr. Richard Markus, a seasoned biotech executive who previously worked for companies such as Amgen, Allergan and MannKind, shares his insights on what makes the Greater Los Angeles Region a fertile ground for new biotech firm formation, and how to successfully attract adequate funding to pursue bioscience R&D activities to serve unmet needs.

      • Richard Markus, MD, PhD, CEO, Dantari Pharmaceuticals
9:35 AM—10:15 AM

Chairman’s Symposium on Made-in-LA Healthcare Innovations

Since WW II, the Greater Los Angeles Region has been the leading hotbed of MedTech innovations, from heart valves, stents, pacemakers and other implantables to surgical tools, medical wearables, and drug delivery devices. Los Angeles-based firms continue to spawn and commercialize MedTech breakthroughs that promise to change the face of medicine. This symposium will shed light on recent innovations based on the interface between engineering and neurosciences that may result in bionic devices to restore body functions or cure difficult-to-treat medical conditions.

Moderator:

      • Thomas Lobl, PhD, Entrepreneur-in-Residence, AMI-USC, and Member of the SoCalBio Innovation Catalyst Program

Presentations:

      • “Medical Robotics Has an Incredibly Exciting Future: A Look at the Alfred Mann Foundation’s Bionic Arm,” by Robert Greenberg, MD, PhD, Executive Chairman, Alfred Mann Foundation
      • “The Orion Project for Restoring Useful Vision to the Blind and Severely Visually Impaired,” by Will McGuire, CEO, Second Sight Medical Products
      • “Neuromodulation Devices to Treat a Wide-Spectrum of Disorders, Including ADHD,” by Ian A. Cook, MD, CMO, NeuroSigma
10:15 AM—10:45 AMNetworking Break
10:45 AM—12:02 PM

Emerging Company Presentations (Three Parallel Tracks of biotech, device and digital health investment pitches)

Biotech Presentations (Barcelona/Casablanca Room):

Moderators:

    • Charles McWilliams, VP, VWR, and Member of the SoCalBio Innovation Catalyst Program
    • Stephen Williams, PhD, Partner, Catalyst Advisors, L.P., and Member of the SoCalBio Innovation Catalyst Program

Presenting Companies:

10:50 AM IntelliStem Technologies (Immunotherapy for cancer)
11:02 AM Cell Care Therapeutics (Immunotherapy for retinal disease)
11:14 AM Signa Therapeutics (Biomarkers and therapeutics for brain disorders)
11:26 AM MyoGene Bio (Gene-editing therapy for Duchenne Muscular Dystrophy)
11:38 AM Basilard BioTech (Nano-mechanical gene delivery platform)
11:50 AM Breakthrough Genomics (Software for interpreting whole genome and whole exome data)

Device Presentations (Melbourne/Naples Room):

Moderators:

    • George Colindres, Attorney, Perkins Coie, and Member of the SoCalBio Innovation Catalyst Program
    • Steve Maylish, CEO, Fusion Biotech, and Member of the SoCalBio Innovation Catalyst Program

Presenting Companies:

10:50 AM WhisperSom Corporation (Device for sleep apnea)
11:02 AM Cactus Medical (Pediatric ear care)
11:14 AM ValVention Inc. (Transcatheter heart assist device)
11:26 AM Platinum Group Coatings LLC (High-performance electrodes for sensor and stimulator applications)
11:38 AM Capillary Biomedical, Inc. (Novel infusion set to deliver insulin to diabetics)
11:50 AM ReSymmetry (Smart robotic seating system that integrates movement into the sitting position transforming the sitting to active sitting)

Digital Health Presentations (Tokyo/Vancouver):

Moderators:

    • William Dolphin, PhD, Cue Squared, and Member of the SoCalBio Innovation Catalyst Program
    • Wendie Johnston, PhD, Pasadena Bio Collaborative Incubator, and Member of the SoCalBio Innovation Catalyst Program

Presenting Companies:

10:50 AM HIA (Human Interface Agent platform for telemedicine)
11:02 AM Asprodental (SaaS platform that can save dentists an hour per day on managing operations and health records)
11:14 AM Vayu Technology (A wearable sensor and AI-driven SaaS solution that provides a wealth of biomechanics data and insights)
11:26 AM Expy Health (Orthopedic pre– and post-surgery patient monitoring)
11:38 AM Eyedaptic (Simulated Natural Vision Eyewear for AMD)
11:50 AM MediMixer (Pediatric medication adherence)

12:15 PM—12:45 PM

Luncheon

Amgen’s Luncheon Plenary Sessions

12:45 PM—1:35 PM

Cancer Moonshots: Do They Matter?

Congress passed the 21st Century Cures Act in December 2016, authorizing $1.8 billion in NIH funding for the Cancer Moonshot over 7 years. This initiative seeks to accelerate the development of cancer cures by tapping the innovative energies of all stakeholders in the private, public and academic sectors who are engaged in oncology R&D. Learn what is new at NCI’s Cancer Moonshot Initiative, and how emerging oncology companies can benefit.

Moderator:

      • Peter Blaisdell, PhD, Independent Consultant, Drug and Biologic Development, and Chair, SoCalBio Innovation Catalyst Program

Introductory Presentation:

      • Patricia Weber, DrPH, Program Director, SBIR Development Center, NCI, NIH

Panelists (each will speak about what is next in their oncology pipeline and whether the “moonshot” approach can help further R&D efforts):

      • Adrian Bot, MD, PhD, VP, Translational Medicine, Kite, a Gilead Company
      • Jim Caggiano, CEO, Dendreon
      • Chris DeRespino, Executive Director, Business Development, Amgen
1:40 PM—2:30 PM

Trends in Corporate Venture Capital & Strategic Partnering

Corporate VC funding has been on the rise lately. For larger biopharma and medical device corporations, having venture arms to invest in startups can be a way of outsourcing some of their R&D efforts in new and unproven technologies without assuming all of the costs and risks. This panel will explore if corporate interest in venture investing will persist. Also, speakers will discuss if increased corporate VC funding may benefit more startups or will it simply drive prices higher for a select few?

Moderator:

      • Joseph Boystak, Managing Partner, Health2047 Capital Partners

Speakers:

      • Kara Bortone, PhD, Sr. Director Portfolio Sourcing & Management, J&J Innovation
      • John Donello, PhD, Vice President, Research Pharmacology, Allergan
      • Kanad Das, PhD, Executive Director, Boehringer Ingelheim Venture USA Inc.
2:30 PM—2:40 PNetworking Break
2:40 PM—3:40 PM

Emerging Company Presentations (Three Parallel Tracks of biotech, device and digital health investment pitches)

Biotech Presentations (Barcelona/Casablanca Room):

Moderators:

    • Mohammad Kondri, Trade Commissioner, Consulate General of Canada and Member of the SoCalBio Innovation Catalyst Program
    • Michael Reilly, President & CEO, Excelse Bio

Presenting Companies:

2:40 PM Capricor Therapeutics (First-in-class biological therapies for the treatment of rare diseases)
2:52 PM Nammi Therapeutics (Drug delivery using nanoparticles)
3:04 PM O-Ray Pharma (Treatment of ear diseases)
3:16 PM ELF Aesthetics (Developing fat reduction technology for refined body contouring)
3:28 PM U-Defi (Skincare that fits the person’s molecular profile)

Diagnostics (Melbourne/Naples Room):

Moderators:

    • Lara Dueppen, PhD, Partner, Perkins Coie, and Member of the SoCalBio Innovation Catalyst Program
    • Hal Lieberman, Sr. Associate, Exceleration Management, and Member of the SoCalBio Innovation Catalyst Program

Presenting Companies:

2:40 PM R&D Ab (Biomarker for sepsis)
2:52 PM Spectral Platforms (Rapid diagnosis of sepsis)
3:04 PM Velox Biosystems (Rapid, ultra-sensitive, single-cell detection and quantification platform technology)
3:16 PM CytoChip (Developing a point of care IVD with its first panel for CBC)
3:28 PM Embryologic (An embryo diagnostic imaging device)

Imaging, Screening and Cardio Devices (Tokyo/Vancouver Room):

Moderators:

    • Bill Lewis, Executive VP, Bolton & Company, and Member of the SoCalBio Innovation Catalyst Program
    • Steve Goldman, Member, Keiretsu Capital, and Member of the SoCalBio Innovation Catalyst Program

Presenting Companies:

2:40 PM bioProtonics, Inc. (Magnetic Resonance (MR) based diagnostic method, MR-μTextureTM, that provides measurements of biologic tissue changes at a resolution far beyond the capability of current clinical diagnostic imaging)
2:52 PM Veriskin (Skin cancer screening)
3:04 PM Modulim (Light-based techniques for non-invasive diagnostics and therapeutic monitoring applications in medicine)
3:16 PM Noninvasix, Inc. (Optoacoustic monitoring of cerebral venous oxygenation to accurately measure the amount of oxygen a baby is receiving in real time)
3:28 PM Leap Biomed (R&D to bring new medical devices to market)

3:40 PM—3:50 PMNetworking Break
3:50 PM—4:40 PM

Parallel Breakout Sessions (Group I):

1. Maximize your Chances of Getting Government Funding (Barcelona/Casablanca Room):

The use of non-dilutive funds should be an important component of your fundraising strategy. Such funding has many benefits as it helps in securing cash without sacrificing equity. It also provides important validation of the team and technology thereby helps in follow-on rounds of funding from private equity and other investors. This session will provide tips on how to improve your chances of getting such funding from government sources including NIH, DoD, and BARDA

Moderator:

      • David Hood, President & CEO, Dh3 Associates

Panelists:

      • Christine Densmore, MS, Program Director: Division of Digestive Diseases and Nutrition. NIH
      • Ross Donaldson, MD, MPH, President & CEO, Critical Innovations LLC
      • Robert Terbrueggen, PhD, President & CEO, DxTerity Diagnostics
      • Patricia Weber, DrPH, Program Director, SBIR Development Center, NCI, NIH

2. Why Science Needs Story: How to Effectively Communicate your Technology Platform to Various Stakeholders (Melbourne/Naples Room):

Effective communication of your company’s science and business strategy to various stakeholders and investors is crucial. This breakout session will help you formulate your company’s narrative in a manner that makes it both engaging and, at the same time, faithful to the scientific evidence needed to generate and gain investor support.

Moderator:

      • Gregory Zikos, Director of Business Development Strategy, AMIUSC

Panelists:

      • April Beyer, CEO, LEVEL Connections.
      • Randy Olson, Founder and Director, Story Circles Narrative Training
      • Gaylene Xanthopoulos, Founder and President, The Leadership Edge

3. Meet the Angels: Optimizing your Chances of Attracting Seed Capital to your Startup (Tokyo/Vancouver Room)

Southern California is home to a number of organized angel investors that are active in the biotech, MedTech and digital health industries. Many emerging companies that first made presentations at the Annual SoCalBio Conference ended up with seed or early-stage funding deals from these angels. The list includes companies such as Neural Analytics (West Los Angeles), Episona (Glendale), Allegro Ophthalmic (San Juan Capistrano), and Capillary Biomedical (Irvine). In this breakout, you will have a chance to hear from and meet these angels. You will learn how to position your company to attract funding from organized individual investors or “super angels.”

Moderator:

      • Steve Goldman, Member, Keiretsu Forum and Member of the SoCalBio Innovation Catalyst Program

Presenters:

      • Fred Haney, President, Venture Management
      • Kristin Hiibner, PhD, Board Member, Pasadena Angels
      • Lori Mills, Angel Investor, Tech Coast Angels
      • Lei Tang, PhD, Angel Investor
      • Matt Thompson, SVP, Tech Coast Angels & Skyview Capital
      • Vuong Trieu, PhD, CEO, Autotelic Inc.
      • Ryan Witt, PhD, Investor, TechCoast Angels
4:40 PM—5:30 PM

Parallel  Breakout Sessions (Group II):

1. When Can You Tap Foreign Money and/or Forge International Strategic Partnerships (Barcelona/Casablanca Room):

Speakers will share their insights on doing international business, particularly with countries such as China, Japan, and India. Issues to be addressed include culture and language differences affecting negotiation and deal closing norms, intellectual property concerns, regulations and reporting requirements, tariffs and currency controls, regulatory concerns, such as CFIUS and FIRRMA.

Moderator:

      • Calvin Chen, CEO, CrossLinkBio

Panelists:

      • Jasmin Patel, President, A-Connect Inc.
      • Naoki Sakurai, PhD, President and CEO, Tanabe Research Laboratories
      • Michael Wise, Partner, Perkins Coie

2. Business Strategy to Build an Edge and Win the Battle of Differentiation (Melbourne/Naples Room):

Speakers will outline the processes of creating and capturing uncontested market space, winning the battle for differentiation, and making the competition irrelevant.

Moderator:

      • Gregory Zikos, Director of Business Development Strategy, AMI-USC

Panelists:

      • Michael Giardello, PhD, Partner, Mount Wilson Ventures
      • Soraya M. Scroggins, Managing Director, Investment Banking and Global Healthcare, Barclays
      • David Sykes, Business Strategy Consultant
      • Tyler Tarr, Partner, Marconi Capital

3. Meet Local Venture Investors (Tokyo/Vancouver Room):

The SoCalBio Conference provides a forum for local funds interested in emerging bioscience technologies to identify suitable investment targets. During this breakout, you will get to meet some of these funds and learn how to position your firm to raise capital from local institutional sources.

Moderator:

      • Alex Suh, Managing Director, California Technology Ventures

Panelists:

      • Alice Cheng, PhD, Associate, Upfront Ventures
      • Chris Bostick, PhD, OCV Partners
      • Cristina Escoda, Managing Director, Tachyon Ventures
      • David Lee, Managing Partner, Solve Ventures
      • Jerry Chen, Associate, Mucker Capital
      • John Shen, Founding Partner, Sunstone Management Inc.
      • Joseph Kim​, VP, Takenaka Partners
      • Kara Bortone, PhD, J&J Innovation
      • Kwame Ulmer, Partner, WaveMaker Three-Sixty Health LP
      • Lu Zhang, Founder & Managing Partner, Fusion Fund
      • Richard Weil, Partner, Mount Wilson Ventures
      • Victor Subandhi, General Partner, Blangkond Ventures

​​

5:30 PM—7:00 PM

Concluding Remarks & Networking Reception

7:00 PMConference Adjourns